ARON SIGNED
Assay-Ready Organ Network
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ARON project word cloud
Explore the words cloud of the ARON project. It provides you a very rough idea of what is the project "ARON" about.
Project "ARON" data sheet
The following table provides information about the project.
| Coordinator |
INSPHERO AG
Organization address contact info |
| Coordinator Country | Switzerland [CH] |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-01-01 to 2020-06-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | INSPHERO AG | CH (SCHLIEREN) | coordinator | 50˙000.00 |
Map
Project objective
In drug development, there is an urgent need for more physiological and predictive pre-clinical in-vitro assays to test the efficacy and toxicity of compounds. This to allow new medicines to be brought to the market quicker and safer. With the growing biological complexity of today’s diseases, it is vital to have interconnected 3D tissue structures of multiple organs in order to investigate biological cross-talk. Today, such physiological and predictive pre-clinical in-vitro assays are not available. Here, InSphero presents ARON, their Assay-Ready Organ Network, to address the urgent need for more physiological and predictive pre-clinical in-vitro assays and aims to study the feasibility of a successful market introduction. ARON is the most advanced modular in-vitro assay platform and will set a new standard for a wide range of cell-based pre-clinical testing by shifting the organ-on-a-chip technology from a late-stage, luxury service to routinely used ready-to-use assays. This enables pharma and biotech companies to develop drugs in a faster and more efficient way, without the use of animals. All elements and process steps guarantee routine implementation for everyone, while experimental complexity is minimized. ARON has the unique option that the consumables are assay-ready, directly shipped on-site, on-demand, and worldwide. InSphero is a leading supplier of organotypic in-vitro 3D microtissues for predictive drug testing and has grown yearly by 40% in the past years. ARON will turn today's service possibilities into a scalable product and will enable to offer assays for highly competitive pricing. The (USA dominated) 3D tissue market is expected to grow with CAGR of 63% to reach a market size of 1.5 billion EUR in 2024. A successful market introduction will impact the EU’s society and economy by creating hundreds of jobs, accelerating drug development that will improve the health of EU-citizens, while reducing cost, time-to-market and the need for animal testing
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ARON" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ARON" are provided by the European Opendata Portal: CORDIS opendata.